Related Experiment Video
Updated: Jun 22, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
IL-2, IFN-gamma, and IL-12 gene polymorphisms and susceptibility to multiple sclerosis
Mohammad Ali Shokrgozar1, Sheila Sarial, Aliakbar Amirzargar
1National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran.
Background:
Multiple sclerosis (MS) is a multifactorial disease. Positive genetic background could predispose individuals to this chronic disabling disease. In order to investigate the role of some proinflammatory cytokines (interleukin (IL)-2, IL-12, and interferon-gamma (IFN-gamma)) as a risk factor for MS, this study was performed.
Methods:
Two hundred and eleven patients with relapsing-remitting form of MS were enrolled in this study and compared with 359 healthy individuals. Using polymerase chain reaction based on sequence-specific primer method, the cytokine genes were amplified, and alleles and genotypes were detected on gel electrophoresis.
Results:
Significant increases for IFN-gamma AT (+874) genotype (54.5% vs. 37.8%, p = 0.0002) and IL-12 AA (-1188) genotype (60.8% vs. 49.7%, p = 0.014) were found in MS patients in comparison with healthy controls. A significant decrease in IFN-gamma TT (+874) genotype (17.7% vs. 27.5%, p = 0.01) and IL-12 CA (-1188) genotype (30.9% vs. 45%, p = 0.001) in MS patients was also detected. No significant differences of IL-2 G/T (-330) and IL-2 G/T (+166) in alleles and genotypes were observed between MS patients and normal subjects.
Conclusions:
It could be suggested that the genetic variation in IL-12 A/C (-1188) and IFN-gamma A/T (+874) cytokine genes could be risk factors for MS patients.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Multiple Sclerosis l: Introduction
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Single Nucleotide Polymorphisms-SNPs
Inhibitors of Viral Protein Synthesis